Skip to main content
Premium Trial:

Request an Annual Quote

Too Soon to Tell

The Boston Globe has a story on the value of genomic data in healthcare. All the new personal genomics companies tout that knowing your genes will lead to better health, but in the article David Altshuler and others say that it is a little too early. "The field is in such horrendous flux that you can't really say for sure that this gene variant is related to this disease and how much, and that will be a moving target for the next few years," says the CDC's Muin Khoury.

The Scan

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.